Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bipartisan Support Pushes FDA User Fee Bill One Step From Passage

This article was originally published in The Tan Sheet

Executive Summary

The Senate is expected to vote this week on the bipartisan compromise of the FDA user fee and reform legislation, which the House overwhelmingly passed in a voice vote June 20. Senate review of the bill will coincide with the Supreme Court’s decision on the health care reform law.

You may also be interested in...



FDA Drug Detention Regulation Follows Devices Oversight Model

A proposed rule implementing new FDASIA authority to administratively detain drugs believed to be adulterated or misbranded largely mirrors regulations already in place for medical devices, FDA says.

FDA Drug Detention Regulation Follows Devices Oversight Model

A proposed rule implementing new FDASIA authority to administratively detain drugs believed to be adulterated or misbranded largely mirrors regulations already in place for medical devices, FDA says.

FDA Could Publish Drug GMP Data To Nudge Manufacturing Improvements

Batch failure and other measures manufacturers commonly track could be aggregated into an industry-wide index FDA would use to help make inspection decisions. CDER compliance chief Howard Sklamberg says FDA wants more predictive measures to find quality issues, rather than lagging metrics such as recalls or adverse events.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel